Lineage Treasury Stock vs Accounts Payable Analysis

LCTX Stock  USD 0.61  0  0.23%   
Lineage Cell financial indicator trend analysis is infinitely more than just investigating Lineage Cell Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lineage Cell Therapeutics is a good investment. Please check the relationship between Lineage Cell Treasury Stock and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Treasury Stock vs Accounts Payable

Treasury Stock vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lineage Cell Therapeutics Treasury Stock account and Accounts Payable. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Lineage Cell's Treasury Stock and Accounts Payable is 0.11. Overlapping area represents the amount of variation of Treasury Stock that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Lineage Cell Therapeutics, assuming nothing else is changed. The correlation between historical values of Lineage Cell's Treasury Stock and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Treasury Stock of Lineage Cell Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Treasury Stock i.e., Lineage Cell's Treasury Stock and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.11
Relationship DirectionPositive 
Relationship StrengthInsignificant

Treasury Stock

Accounts Payable

An accounting item on the balance sheet that represents Lineage Cell obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lineage Cell Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Lineage Cell's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lineage Cell Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
At this time, Lineage Cell's Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 206.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 11 M in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses51.7M36.5M33.0M21.0M
Cost Of Revenue1.4M728K671K583.4K

Lineage Cell fundamental ratios Correlations

0.590.86-0.57-0.710.10.620.760.750.480.380.550.750.750.860.440.01-0.260.66-0.630.570.780.830.510.45-0.53
0.590.19-0.65-0.65-0.090.670.70.620.880.80.970.810.290.190.02-0.14-0.030.68-0.360.910.590.60.280.93-0.21
0.860.19-0.3-0.450.140.340.50.550.090.150.140.520.640.870.340.15-0.220.34-0.570.250.560.620.390.04-0.38
-0.57-0.65-0.30.470.1-0.99-0.65-0.42-0.36-0.57-0.52-0.6-0.3-0.33-0.320.020.23-0.420.31-0.65-0.48-0.48-0.13-0.550.32
-0.71-0.65-0.450.470.03-0.55-0.81-0.97-0.74-0.18-0.72-0.62-0.72-0.49-0.16-0.050.19-0.950.62-0.38-0.97-0.97-0.57-0.680.34
0.1-0.090.140.10.03-0.1-0.11-0.05-0.21-0.02-0.160.030.170.150.350.430.0-0.160.10.05-0.05-0.01-0.01-0.29-0.32
0.620.670.34-0.99-0.55-0.10.70.510.40.540.550.630.40.370.35-0.03-0.220.52-0.390.640.560.560.250.58-0.33
0.760.70.5-0.65-0.81-0.110.70.790.70.430.720.850.660.420.29-0.03-0.180.77-0.570.60.760.80.560.65-0.39
0.750.620.55-0.42-0.97-0.050.510.790.710.230.690.620.70.540.110.05-0.170.92-0.690.360.980.980.560.65-0.23
0.480.880.09-0.36-0.74-0.210.40.70.710.550.970.670.270.12-0.13-0.22-0.110.8-0.320.660.660.660.310.94-0.13
0.380.80.15-0.57-0.18-0.020.540.430.230.550.690.73-0.04-0.03-0.05-0.080.190.2-0.20.910.150.17-0.010.650.05
0.550.970.14-0.52-0.72-0.160.550.720.690.970.690.760.290.16-0.06-0.18-0.070.76-0.350.80.650.650.310.96-0.18
0.750.810.52-0.6-0.620.030.630.850.620.670.730.760.560.320.23-0.030.110.58-0.460.840.570.620.470.64-0.36
0.750.290.64-0.3-0.720.170.40.660.70.27-0.040.290.560.650.520.160.020.68-0.670.210.730.770.830.18-0.58
0.860.190.87-0.33-0.490.150.370.420.540.12-0.030.160.320.650.480.05-0.420.43-0.520.180.630.670.360.09-0.51
0.440.020.34-0.32-0.160.350.350.290.11-0.13-0.05-0.060.230.520.48-0.110.150.13-0.390.110.170.210.3-0.13-0.38
0.01-0.140.150.02-0.050.43-0.03-0.030.05-0.22-0.08-0.18-0.030.160.05-0.11-0.09-0.06-0.14-0.070.040.06-0.08-0.22-0.29
-0.26-0.03-0.220.230.190.0-0.22-0.18-0.17-0.110.19-0.070.110.02-0.420.15-0.09-0.16-0.240.04-0.28-0.270.18-0.110.36
0.660.680.34-0.42-0.95-0.160.520.770.920.80.20.760.580.680.430.13-0.06-0.16-0.630.380.930.910.640.77-0.25
-0.63-0.36-0.570.310.620.1-0.39-0.57-0.69-0.32-0.2-0.35-0.46-0.67-0.52-0.39-0.14-0.24-0.63-0.25-0.65-0.66-0.63-0.36-0.04
0.570.910.25-0.65-0.380.050.640.60.360.660.910.80.840.210.180.11-0.070.040.38-0.250.330.370.170.71-0.28
0.780.590.56-0.48-0.97-0.050.560.760.980.660.150.650.570.730.630.170.04-0.280.93-0.650.330.990.550.63-0.34
0.830.60.62-0.48-0.97-0.010.560.80.980.660.170.650.620.770.670.210.06-0.270.91-0.660.370.990.580.6-0.4
0.510.280.39-0.13-0.57-0.010.250.560.560.31-0.010.310.470.830.360.3-0.080.180.64-0.630.170.550.580.25-0.21
0.450.930.04-0.55-0.68-0.290.580.650.650.940.650.960.640.180.09-0.13-0.22-0.110.77-0.360.710.630.60.250.0
-0.53-0.21-0.380.320.34-0.32-0.33-0.39-0.23-0.130.05-0.18-0.36-0.58-0.51-0.38-0.290.36-0.25-0.04-0.28-0.34-0.4-0.210.0
Click cells to compare fundamentals

Lineage Cell Account Relationship Matchups

Lineage Cell fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets125.5M107.9M174.5M123.7M101.0M106.1M
Total Current Liabilities6.5M7.8M47.1M19.0M18.0M18.9M
Total Stockholder Equity113.0M96.2M92.2M73.3M63.4M33.3M
Net Debt(4.3M)(29.3M)(52.9M)(7.5M)(32.5M)(30.9M)
Retained Earnings(273.4M)(294.1M)(337.1M)(363.4M)(384.9M)(365.6M)
Accounts Payable5.2M2.6M3.5M2.4M2.0M2.1M
Cash9.5M32.6M55.7M11.4M35.4M37.2M
Cash And Short Term Investments30.7M41.6M58.4M57.9M35.5M37.3M
Common Stock Shares Outstanding145.5M150.0M164.5M169.8M172.7M181.3M
Liabilities And Stockholders Equity125.5M107.9M174.5M123.7M101.0M106.1M
Non Current Liabilities Total7.7M5.1M36.5M32.7M21.0M22.1M
Other Stockholder Equity(681K)(3.7M)433.2M(3.6M)(1.4M)(1.3M)
Total Liab14.2M12.8M83.6M51.7M39.0M40.9M
Total Current Assets57.5M44.0M111.5M60M38.4M21.1M
Property Plant And Equipment Net8.2M5.6M4.9M5.7M4.8M5.0M
Non Current Assets Total68.0M64.0M63.0M63.7M62.6M65.7M
Non Currrent Assets Other864K616K630K627K577K556.9K
Other Assets864K616K630K627K564.3K536.1K
Other Current Assets2.9M2.4M2.4M1.8M2.2M1.4M
Property Plant And Equipment Gross8.2M5.6M10.2M11.5M12.0M12.6M
Accumulated Other Comprehensive Income(681K)(3.7M)(5.2M)(3.6M)(3.1M)(2.9M)
Other Current Liab2.8M3.4M24.6M6.2M3.3M3.7M
Common Stock Total Equity387.1M393.9M434.5M440.3M506.3M531.6M
Common Stock387.1M393.9M434.5M440.3M451.3M473.9M
Short Long Term Debt Total5.2M3.3M2.8M3.9M3.0M3.0M
Current Deferred Revenue45K193K18.1M9.4M10.8M11.3M
Short Term Debt1.2M1.5M831K952K1.8M1.9M
Intangible Assets48.2M47.0M46.8M46.7M46.6M33.7M
Net Tangible Assets54.0M38.5M34.7M16.0M18.4M17.5M
Noncontrolling Interest In Consolidated Entity(1.7M)(1.1M)(1.3M)(1.4M)(1.3M)(1.2M)
Retained Earnings Total Equity(273.4M)(294.1M)(337.1M)(363.4M)(327.0M)(343.4M)
Non Current Liabilities Other4.2M3.0M2.0M2.9M3.4M3.6M
Property Plant Equipment8.2M5.6M4.9M5.7M6.5M6.0M
Net Receivables23.9M4K50.8M297K745K707.8K
Other Liab3.8M2.5M34.6M29.8M34.3M36.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.